IGF1 treatment has been shown to reverse some of the neurophysiological abnormalities in a mouse model of Rett Syndrome lacking methyl CpG-binding protein 2 (Mecp2 [46]). This evidence concerns the gene MECP2 and atypical Rett syndrome.